Real-World Studies
Consolidation Durvalumab Linked to Longer Survival in Unresectable Stage III NSCLC
Rai et alJournal of Clinical Medicine

In a retrospective cohort study analyzing the N-Power Medicine database, investigators evaluated real-world clinical outcomes and treatment patterns in 717 adult patients with unresectable stage III non-small cell lung cancer (NSCLC) who initiated concurrent chemoradiotherapy (cCRT) between February 2018 and October 2023, with follow-up through October 2025. Following cCRT, 487 patients received consolidation durvalumab, whereas 230 patients received cCRT alone.
Patients treated with consolidation durvalumab experienced longer survival and delayed distant recurrence compared to those receiving cCRT alone. Median overall survival reached 42.6 months in the durvalumab cohort versus 11.4 months in the cCRT-only cohort, with overall survival events occurring in 55.2% and 80.0% of patients, respectively. In the durvalumab group, overall survival rates at 12, 36, and 60 months were 83.6%, 56.0%, and 42.8%. Median time to death or distant metastasis was 26.7 months with durvalumab versus 5.6 months with cCRT only. Disease progression occurred in 40.9% of durvalumab-treated patients compared with 48.7% of cCRT-only patients. The authors concluded that approximately one-third of patients in real-world practice did not receive consolidation durvalumab following cCRT, and noting that disease progression continues to occur in a substantial proportion of patients despite consolidation therapy, an unmet need remains in this population.
Key Takeaways
- Consolidation durvalumab following concurrent chemoradiotherapy (cCRT) achieved a median overall survival of 42.6 months compared with 11.4 months for cCRT alone, alongside an extended median time to death or distant metastasis of 26.7 months versus 5.6 months.
- Patients receiving durvalumab consolidation experienced lower rates of overall survival events (55.2% vs. 80.0%) and lower disease progression rates (40.9% vs. 48.7%) relative to the cCRT-only cohort, with 12-, 36-, and 60-month overall survival rates reaching 83.6%, 56.0%, and 42.8%.
- Approximately one-third of patients with unresectable stage III non-small cell lung cancer (230 of 717) did not receive durvalumab consolidation following cCRT in real-world practice.
Read the original sourceJournal of Clinical Medicine
